Entero Healthcare Solutions Limited · NSE:ENTERO
Entero Healthcare Solutions — Q2 FY27 Earnings Presentation
39 slides from Entero Healthcare Solutions's earnings presentation, November 2026
Slide 1: Entero Healthcare Solutions Limited Q2FY27 Investor Presentation
Everything in Pharma… Everywhere in India… Entero Healthcare Solutions Limited Q2FY27 Investor Presentation – November 2026
Slide 2: Safe Harbour
Safe Harbour This presentation and the accompanying slides (the “Presentation”), which have been prepared by Entero Healthcare Solutions Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe
Slide 3: Q2 FY27 Financial Highlights
Q2 FY27 Financial Highlights
Slide 4: Management Commentary
Management Commentary We continued the strong organic growth momentum outpacing industry growth and sustained improvement in EBITDA margin in the second quarter. Our revenue grew by 34.7% YoY (LFL) with EBITDA margin at 5.3%. We are pleased with the performance in first half of the year and are on t
Slide 5: H1FY27 - Key Financial Highlights
H1FY27 - Key Financial Highlights › Revenue growth on LFL basis was 37.2% YoY. Organic revenue growth on LFL basis was 19.8% YoY. Like-for-Like growth includes impact of revenue recorded on net margin basis and divestment of a subsidiary › Reported revenue growth was 35.4% YoY. Organic revenue growt
Slide 6: Q2FY27 - Key Financial Highlights
Q2FY27 - Key Financial Highlights › Revenue growth on LFL basis was 34.7% YoY. Organic revenue growth on LFL basis was 20.0% YoY. Like-for-Like growth includes impact of revenue recorded on net margin basis and divestment of a subsidiary › Reported revenue growth was 32.9% YoY. Organic revenue growt
Slide 7: Revenue Split
Revenue Split +32.9% +14.7% 2,087 +18.2% 1,571 Q2FY26 Revenue Organic Growth Calendarisation New Acquisitions Q2FY27 Revenue Particulars Q1FY26 Q2FY26 Q3FY26 Q4FY26 FY26 Q1FY27 Q2FY27 H1FY27 Organic Growth 12.0% 10.7% 14.2% 16.6% 13.4% 17.8% 18.2% 18.0% Organic growth - LFL 15.0% 13.4% 17.1% 17.1% 1
Slide 8: Consolidated Financial Highlights
Consolidated Financial Highlights Revenue (Rs. Cr) Gross Profit (Rs. Cr) & Margin (%) EBITDA (Rs. Cr) & Margin (%) PAT (Rs. Cr) +33% +49% +78% +66% 2,087 240 111 61 Quarter 1,571 161 62 37 10.2% 11.5% 5.3% 4.0% 2.9% 2.3% Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Revenue (Rs. Cr) Gross
Slide 9: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. Cr) Q2FY27 Q1FY27 Q2FY26 YoY% H1FY27 H1FY26 YoY% Revenue 2,087.1 1,940.5 1,570.9 33% 4,027.6 2,974.8 35% Cost of Goods Sold 1,847.1 1,719.1 1,410.1 3,566.2 2,674.4 Gross Profit 240.0 221.4 160.8 49% 461.3 300.4 54% Gross Margin (%) 11.5% 11.4% 10
Slide 10: Key Balance Sheet Highlights
Key Balance Sheet Highlights Net Operating Working Capital (Days) RoCE (%) RoE (%) 63 61 64 21.1% 22.0% 22.4% 20.4% 13.8% 11.0% Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Net Operating Working Capital (Days) RoCE (%) RoE (%) 68 66 21.8% 21.3% 11.6% 10.0% H1FY26 H1FY27 H1FY26 H1FY
Slide 11: Entero's FY27 MedTech revenue expected to cross Rs. 1,000 Cr
Entero’s FY27 MedTech revenue expected to cross Rs. 1,000 Cr MedTech Industry Overview (USD bn) Strategic rationale for acquisitions in MedTech market 45-50 MedTech is large and a growing market Synergistic with Entero’s pharmaceutical distribution 13-13.5 Attractive and significant consolidation op
Slide 12: Operational Highlights
Operational Highlights Outperforming Customers Relationship with Market Growth SKU’s Handled (Retailers) healthcare product (H1FY27) manufacturers Entero: 37.2% › H1FY27: 92,200+ › H1FY27: 90,400+ › H1FY27: 3,200+ IPM: 14.5% › H1FY26: 85,300+ › H1FY26: 83,000+ › H1FY26: 2,800+ Customers Districts Co
Slide 13: Growing faster than Industry… Gaining Market Share
Growing faster than Industry… Gaining Market Share IPM Entero Organic Growth Entero Consolidated Growth 43%* 40%* 38% 37% 35% 35% 35%* 31% 31% 31%* 29%* 28%* 23%* 22% 19% 19% 19% 20% 20%* 20%* 16% 17% 17%* 17%* 15% 15% 14% 15%* 18% 17% 17% 13%* 15% 16% 15% 11%* 14% 9% 10% 9% 12% 12% 7% 9% 12% 9% 9%
Slide 14: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (Rs Cr.) Sep-26 Mar-26 EQUITY AND LIABILITY (Rs Cr.) Sep-26 Mar-26 Non-current assets Equity Equity Share capital 44 44 Property, plant and equipment 115 103 Share Application Money Pending Allotment 4 0 Other intangible assets 13 11 Other equity 1,734 1,645 Right o
Slide 15: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Cr) H1FY27 H1FY26 Net Profit Before Tax 145.5 81.0 Adjustments for: Non-Cash Items / Other Investment or Financial Items 75.9 36.5 Changes in working capital -245.0 -148.9 Direct taxes paid (net of refund) -22.9 -25.9 Net Cash from Operating Activiti
Slide 16: About Us
About Us
Slide 17: We are a Healthcare Supply Chain Solutions Specialist
We are a Healthcare Supply Chain Solutions Specialist Amongst the top three healthcare products distributors in India in terms of revenue Our Warehouses Fastest scale-up of operations among healthcare products distributors in India with track record of 51 acquisitions Pan-India presence through our
Slide 18: Entero at a Glance
Entero at a Glance Geographical Reach of Distribution Network 92,200+ 2,900+ 3,200+ Customers Retail customers Hospital Supply relationships with catered to customers healthcare product manufacturers AMRITSAR PANCHKULA DEHRADUN KARNAL DELHI GHAZIABAD GURGAON NOIDA FARIDABAD JAIPUR GORAKHPUR LUCKNOW
Slide 19: Building a Highly Scalable Business Model
Building a Highly Scalable Business Model Consolidated Revenue (Rs. Cr) Customers (Retailers) Customers (Hospitals) FY23 81,400+ FY23 3,400+ FY24 86,300+ FY24 3,500+ 6,591 FY25 95,300+ FY25 3,600+ FY26 105,300+ FY26 3,600+ Relationship with healthcare 5,096 SKU’s Handled product manufacturers +30% C
Slide 20: Board of Directors: Governance is our foundation for growth
Board of Directors : Governance is our foundation for growth Sujesh Vasudevan Sandhya Gadkari Sharma Prabhat Agrawal Chairperson and Non-Executive Non-Executive Independent Promoter, Managing Director Independent Director Director and CEO Prem Sethi Arun Sadhanandham Sumona Chakraborty Promoter, Who
Slide 21: Leadership Team
Leadership Team Prabhat Agrawal Prem Sethi Balakrishnan Natesan Kaushik Promoter, Managing Director and CEO Promoter, Whole-time Director and COO Group Chief Financial Officer ◼ Previous experience as CEO with Alkem Laboratories, ◼ Previous experience as Director – Offering Development and ◼ Previou
Slide 22: Leadership Team
Leadership Team Abhitesh Kumar Manish Kumar Sanjay Chakraborty Gaurav Kumar Sandip Dey Siddharth Sood Sanu Kapoor Chief Growth Officer President - Central SVP - Sales & VP - Retail Pharma President - Institutional Chief Technology VP - General Counsel, Procurement & Marketing, MedTech Business Busin
Slide 23: Market Opportunity
Market Opportunity
Slide 24: Pharmaceutical Supply Chain in India is Highly Fragmented
Pharmaceutical Supply Chain in India is Highly Fragmented Player in Value Chain Typical Functions and Role No. of Players Typical Margin range Pharmaceutical and Healthcare Companies ~3,000 Products Manufacturer ▪ Manufacturing units supplying finished products 40 – 60% Man. Units 10,500 ▪ Marketer
Slide 25: Key Challenges in the Pharmaceutical Supply Chain
Key Challenges in the Pharmaceutical Supply Chain Pharmaceutical and Healthcare Products Manufacturer / High expiries due to multiple Complexity of dealing with Limited or no secondary sales No direct reach to retailers, Inadequate storage stock points and no data Marketer multiple sub-scale distrib
Slide 26: Healthcare Products Distribution Market Overview
Healthcare Products Distribution Market Overview Large and Growing Target Addressable Market… …Led by Increasing Share of Large / National Distributors Share of the total distributor sales for Large / National pharmaceutical distributors 20-30% CAGR $33.2bn 10-11% 25-30% 8-10% Target Addressable Mar
Slide 27: Key Strengths
Key Strengths
Slide 28: Key Strengths
Key Strengths We Operate in the Large and Highly Fragmented Indian Healthcare Products Distribution Market and Expect to Benefit from Market Consolidation We are One of India’s Largest and Fastest Growing Healthcare Products Distribution Platforms Track Record of Inorganic Expansion and Integration
Slide 29: Highly Fragmented Market… to Accelerate Consolidation
Highly Fragmented Market… to Accelerate Consolidation US China India(1) Germany Top 3: 90 – 95% Top 4: 40 – 45% Top 3: 8 – 10% Top 5: 95 – 97% Share of Large Players in the Pharma Distribution Top 3 Top 4 Top 3 Top 5 / All Share of Top x 2020 90 – 95% 40 – 45% 8 – 10% 95 – 97% in Total Pharma Distri
Slide 30: Successful track record of Acquisitions and Integration
Successful track record of Acquisitions and Integration Track Record of Growth of Acquired Companies Acquisition Strategy Distributor Name Date of Acquisition Location FY21-23 Growth R.S.M Pharma 14-Aug-2018 Bengaluru ~69% › Take advantage of market consolidation opportunities available Getwell Medi
Slide 31: Differentiated Business Model
Differentiated Business Model Offers both demand generation and demand fulfilment capabilities to healthcare brands and product manufacturers Demand Generation via Integrated Demand Fulfilment via end-to-end healthcare products distribution solutions Commercial Solutions Deploy Medical Representativ
Slide 32: Proprietary Technology Platform
Proprietary Technology Platform with Integrated Business Intelligence Tools and Solutions Technology-Focused Approach Anchored on Our Proprietary Integrated Tech …To Grow our Operations and Bring Efficiencies in the Healthcare Platforms and Business Intelligence Tools… Products Distribution Ecosyste
Slide 33: Key Growth Drivers
Key Growth Drivers Benefit from healthcare products distribution market consolidation with strategic acquisitions Strengthen market position through increases in customer base, wallet share and geographic penetration Pursue comprehensive marketing and distribution collaborations with healthcare prod
Slide 34: Historical Financials
Historical Financials
Slide 35: Historical Financial Highlights
Historical Financial Highlights Revenue (Rs. Cr) Gross Profit (Rs. Cr) and Margin (%) 8.3% 8.1% 9.0% 9.5% 10.3% 6,591 680 +27% +34% 5,096 486 3,922 3,300 352 2,522 268 210 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 EBITDA (Rs. Cr) and Margin (%) Net Operating Working Capital (Days)* 1.0% 1.9%
Slide 36: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Particulars (Rs. Cr) FY26 FY25 FY24 FY23 FY22 Revenue 6,591.2 5,095.8 3,922.3 3,300.2 2,522.1 Cost of Goods Sold 5,910.8 4,609.5 3,570.4 3,031.9 2,312.4 Gross Profit 680.4 486.3 352.0 268.3 209.6 Gross Margin (%) 10.3% 9.5% 9.0% 8.1% 8.3% Employee Expenses 241.9
Slide 37: Consolidated Balance Sheet
Consolidated Balance Sheet ASSETS (Rs. Cr) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 EQUITY AND LIABILITIES (Rs. Cr) Mar-26 Mar-25 Mar-24 Mar-23 Mar-22 ASSETS Equity Non-current assets Equity Share capital 43.5 43.5 43.5 4.1 3.9 Property, plant and equipment 103.1 57.0 41.0 43.2 45.7 Other equity 1,645.1 1
Slide 38: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement Particulars (Rs. Cr) FY26 FY25 FY24 FY23 FY22 Net Profit Before Tax 179.3 138.7 35.6 -3.7 -19.8 Adjustments for: Non-Cash Items / Other Investment or Financial Items 107.1 44.0 86.6 -71.2 -41.5 Operating profit before working capital changes 286.4 182.8 122.2 67.5 21
Slide 39: Investor Relations Contacts
Company: Investor Relations Advisor: CIN: L74999HR2018PLC072204 CIN: U74140MH2010PTC204285 Ms. Akanksha Gupta Mr. Jigar Kavaiya / Parin Narichania E: irentero@ehspl.com E: jigar.kavaiya@sgapl.net / parin.n@sgapl.net T: +91-22-69019100 T: +91 9920602034 / +91 9930025733 www.enterohealthcare.com www.s
Entero Healthcare Solutions — Q2 FY27 Earnings Presentation on 6ix